Clinical trials: SARS-CoV Infection
- Condition SARS-CoV Infection
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
SARS-CoV2 Infection
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)
The primary objective of this study is to provide expanded access of remdesivir (RDV) for the treatment of severe acute respiratory syndrome coronavirus (SARS-CoV2) infection.
- Trial name
- NCT04323761
- Testing
- Remdesivir
- Where
- 272 sites in United States, Australia and 25 more
- Sponsor
- Gilead Sciences
Covid19
Canine COVID-19 Detection
Dogs are some of nature's greatest detectives, owing to their incredible sense of smell and ability to be trained. Most of us will be familiar with seeing trained sniffer dogs at airports looking for drugs and other prohibited…
- Trial name
- NCT04509713
- Testing
- Collection of odour samples
- Where
- United Kingdom
- Volunteers
- 16,250 people, healthy volunteers welcome
- Sponsor
- ARCTEC
SARS-CoV-2 Virus Infection
COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222
This is a multicentre, randomized, observer-blind, active-controlled, superiority, study in adults to compare the immunogenicity of VLA2001 to AZD1222 in terms of GMT of SARS-CoV-2-specific neutralising antibodies.
- Trial name
- COV-COMPARE (NCT04864561)
- Testing
- VLA2001, AZD1222, VLA2001 - adolescent part
- Where
- 31 sites in United Kingdom
- Volunteers
- 4,034 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Coronavirus Infection, Severe Acute Respiratory Syndrome
COVID-19 Seroprevalence Study in French Guiana
Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana.
- Conditions
- Coronavirus Infection, Severe Acute Respiratory Syndrome, SARS-CoV Infection, Covid19
- Trial name
- EPI-COVID-POP (NCT04490850)
- Testing
- Blood sample
- Where
- 5 sites in French Guiana
- Volunteers
- 3,541 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Coronavirus Infections, Severe Acute Respiratory Syndrome
Household Transmission Investigation Study for COVID-19 in Tropical Regions
This study is a interventional study that present minimal risks and constraints to evaluate the presence of novel coronavirus (SARS-CoV-2) or antibodies among individuals living in households where there is a confirmed…
- Conditions
- Coronavirus Infections, Severe Acute Respiratory Syndrome, SARS-CoV Infection
- Trial name
- EPI-COVID-19 (NCT04328129)
- Testing
- Human biological samples
- Where
- 4 sites in French Guiana, Guadeloupe and 1 more
- Volunteers
- 245 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Influenza A, Influenza Type B
FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol
The goal of this observational study is to compare the FINDER FLU A/B, RSV, SARS-CoV-2 Test to an FDA-cleared device. The study will utilize prospectively collected de-identified nasopharyngeal samples obtained from both…
- Conditions
- Influenza A, Influenza Type B, SARS CoV 2 Infection, RSV Infection
- Trial name
- NCT05928507
- Testing
- Diagnostic Test for identification of influenzas A, influenzas B, RSV and SARS-CoV-2 infections
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- Baebies, Inc.
Upper Respiratory Infection
BD Veritor™ At-Home and BD Veritor™ Professional
The BD Veritor™ System is a rapid test that is testing for both COVID-19 and for Influenza This study will try to determine if the BD Veritor™ system can assist in the diagnosis of someone who has upper respiratory infection…
- Trial name
- NCT05352581
- Testing
- BD Veritor At-Home, BD Veritor Professional
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 1,146 people
- Sponsor
- Becton, Dickinson and Company
SARS-CoV Infection
A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research
Minimal risk research study: 1. Comparing polyester nasal swabs and foam nasal swabs to detect SARS-CoV-2 virus; 2. Quantifying the development and trajectory of the disease through clinic visits and blood values.
- Trial name
- NCT04327804
- Testing
- Odd/Even birth year intervention groups
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- UnitedHealth Group
SARS CoV 2 Infection
Open-label, Multi-centre, Non-Inferiority Study of Safety and Immunogenicity of BIMERVAX for the Prevention of COVID-19 in Adolescents From 12 Years to Less Than 18 Years of Age.
This is a Phase IIb, open-label, uncontrolled, multi-centre, non-inferiority clinical trial, to assess the safety and immunogenicity of BIMERVAX® as a heterologous booster dose in adolescents.
- Trial name
- NCT06234956
- Testing
- BIMERVAX
- Where
- 7 sites in Spain
- Volunteers
- 242 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
SARS-CoV Infection, Covid19
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
This is a phase 3, randomized, observer-blinded, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of SARS-CoV-2 rS with Matrix-M1 adjuvant in adult participants and adolescent participants.
- Trial name
- NCT04611802
- Testing
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)
- Where
- 154 sites in United States, Mexico and 1 more
- Volunteers
- 33,000 people, healthy volunteers welcome
- Sponsor
- Novavax
COVID-19, COVID-19 Pandemic
Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Analysis
The purpose of this retrospective study is to evaluate the effectiveness of CPM nasal spray as part of the treatment of COVID-19 and its impact on clinical symptoms. Two cohort groups will be compared (CPM vs. standard care).
- Conditions
- COVID-19, COVID-19 Pandemic, COVID-19 Respiratory Infection, SARS CoV 2 Infection
- Trial name
- ACCROS-R (NCT05520944)
- Testing
- ClorNovir® (Chlorpheniramine) 0.4% Nasal Spray
- Where
- Dominican Republic
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Dr. Ferrer BioPharma